Back To Schedule
Thursday, June 18 • 5:00pm - 6:00pm
#553 OD: ON DEMAND - What Makes Real World Data Trustworthy: A Focus on Design and Data

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate

An number of on-going activities are examining real world data (RWD) and comparing it to data from randomized clinical trials in order to gauge whether the RWD are trustworthy and if they could be a substitute. Although useful to understand these measures, this approach ignores the unique contribution of RWD, particularly in the context of when it can be used to speed access to medical innovations, to understand comparative effectiveness and safety and the the implications of real-world adherence as well as characterize benefits and risks over longer periods of follow-up than are typical for most trials, particularly.

As regulators around the world become more interested in using RWD, current efforts in the US, Europe, and Japan will be discussed along with what they are requesting to provide comfort with the data methods and evidentiary requirements.

Learning Objectives

Discuss current efforts in the US, Europe, and Japan with using real world data to speed access to medical innovations, understand comparative effectiveness, and safety.


Nancy A. Dreyer, PhD, MPH, FISPE


FDA Update
Peter P. Stein, MD

PMDA Update
Yoshiaki Uyama, PhD

avatar for Yoshiaki Uyama

Yoshiaki Uyama

Director, Office of Medical Informatics and Epidemiology, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Dr Yoshiaki Uyama is currently Office Director, Office of Medical Informatics and Epidemiology, Pharmaceuticals & Medical Devices Agency (PMDA) of Japan. He is responsible for all epidemiological activities in PMDA including the projects of MIHARI(Medical Information for risk assessment... Read More →
avatar for Peter Stein

Peter Stein

Director, Office of New Drugs, CDER, FDA, United States
Dr. Peter Stein, M.D., is the Director of CDER’s Office of New Drugs (OND). OND is responsible for the regulatory oversight of investigational studies during drug development and decisions regarding marketing approval for new (innovator or non-generic) drugs, including decisions... Read More →
avatar for Nancy Dreyer

Nancy Dreyer

Chief Scientific Officer & SVP, IQVIA, United States
Nancy Dreyer is Chief Scientific Officer and SVP at IQVIA Real World Solutions and Adjunct Professor of Epidemiology at Univ of N Carolina at Chapel Hill. She leads the IQVIA Center for Advanced Evidence Generation and is a fellow of both the International Society for Pharmacoepidemiology... Read More →

Thursday June 18, 2020 5:00pm - 6:00pm EDT
TBD Virtual Event Horsham, PA 19044
  09: Regulatory, Forum